Announcement • Jun 30
Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026 Aurisco Pharmaceutical Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 Declared Dividend • Jun 10
Dividend increased to CN¥0.34 Dividend of CN¥0.34 is 17% higher than last year. Ex-date: 15th June 2026 Payment date: 15th June 2026 Dividend yield will be 1.8%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (35% earnings payout ratio) but not covered by cash flows (104% cash payout ratio). The dividend has increased by an average of 23% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 26% over the next year, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 17
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥1.12 (up from CN¥0.89 in FY 2024). Revenue: CN¥1.70b (up 15% from FY 2024). Net income: CN¥449.2m (up 27% from FY 2024). Profit margin: 27% (up from 24% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.8%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Apr 17
Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 07, 2026 Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Taizhou, Zhejiang China Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥29.39, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 14% over the past three years. Announcement • Mar 30
Aurisco Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Apr 24, 2026 Aurisco Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥30.69, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 17% over the past three years. Announcement • Dec 26
Aurisco Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 17, 2026 Aurisco Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 17, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.29 (up from CN¥0.24 in 3Q 2024). Revenue: CN¥415.1m (up 16% from 3Q 2024). Net income: CN¥118.6m (up 25% from 3Q 2024). Profit margin: 29% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Aurisco Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Aurisco Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jun 30
Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Aurisco Pharmaceutical Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 New Risk • May 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Price Target Changed • May 06
Price target decreased by 8.1% to CN¥28.00 Down from CN¥30.48, the current price target is provided by 1 analyst. New target price is 32% above last closing price of CN¥21.29. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥0.97 for next year compared to CN¥0.71 last year. Announcement • Apr 26
Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2025 Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Taizhou, Zhejiang China Announcement • Mar 28
Aurisco Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Aurisco Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Jan 22
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) announces an Equity Buyback for CNY 120 million worth of its shares. Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) announces a share repurchase program. Under the program, the company will repurchase up to CNY 120 million worth of its shares. The shares will be repurchased at no more than CNY 25 per share. The purpose of the program is to use the repurchased shares for conversion of the company's convertible bonds. If the repurchased shares are not used for the intended purpose within the statutory period after the repurchase is completed, there is a risk that the unimplemented portion will be fully cancelled. The program will be funded from company's own funds. The program will be valid for 12 months. Announcement • Dec 27
Aurisco Pharmaceutical Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Aurisco Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.32 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.32 in 3Q 2023). Revenue: CN¥357.7m (down 3.3% from 3Q 2023). Net income: CN¥95.2m (down 30% from 3Q 2023). Profit margin: 27% (down from 37% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Aurisco Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Aurisco Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥24.08, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 84% over the past three years. Announcement • Jun 29
Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Aurisco Pharmaceutical Co.,Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • Apr 30
Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 20, 2024 Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Taizhou, Zhejiang China Announcement • Mar 30
Aurisco Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Aurisco Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥19.45, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total returns to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.56 per share. Announcement • Dec 30
Aurisco Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024 Aurisco Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.17 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.32 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥369.9m (up 42% from 3Q 2022). Net income: CN¥136.6m (up 96% from 3Q 2022). Profit margin: 37% (up from 27% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥26.30, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.56 per share. New Risk • Oct 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (dividend per share is over 7x cash flows per share). Share price has been volatile over the past 3 months (6.1% average weekly change). Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.19 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.19 in 2Q 2022). Revenue: CN¥250.5m (down 14% from 2Q 2022). Net income: CN¥50.0m (down 34% from 2Q 2022). Profit margin: 20% (down from 26% in 2Q 2022). The decrease in margin was driven by lower revenue. Announcement • Jun 30
Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China Aurisco Pharmaceutical has good reasons to celebrate. On its 25th anniversary, the high-tech pharmaceutical company dedicated to innovation has received its first Marketing Authorization Approval in China for AUXITON(R), the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA. Aurisco is the only company holding both an active USDMF and a valid CEP -- the Certificate of compliance with the European Pharmacopoeia, issued by the EDQM for the drug substance. As explained by Vivian Shan, MD, Aurisco Pharmaceutical's Medical Manager for this program, "AUXITON(R) provides doctors a safe and convenient, orally bioavailable dydrogesterone - a highly selective progestogen receptor agonist. With an equivalence dose 10--20 times lower than progesterone due to its better bioavailability and the progestogenic nature of the metabolites, dydrogesterone has multiple advantages over natural progesterone, ensuring efficacy and safety to establish the adequate levels for luteal support during natural pregnancy and in-vitro fertilization (IVF). Integrating the production of API, formulation and finished dosage, Aurisco ensures product quality, productivity, and cost advantages throughout the entire industrial chain, to guarantee adequate productivity and stable supply to meet new clinical programs. Following international cGMP and EHS standards, product quality is in line with China, Europe, and United States standards. The company have been working with the best generic pharmaceutical companies in the world, supplying them safe, sustainable, affordable and high-quality products. Leveraging on technologically advanced and differentiated capabilities, also work with innovators, offering contract research, development and manufacturing services (CRDMO). Announcement • Jun 28
Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Aurisco Pharmaceutical Co.,Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Apr 15
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.52 (up from CN¥0.42 in FY 2021). Revenue: CN¥1.01b (up 26% from FY 2021). Net income: CN¥210.9m (up 25% from FY 2021). Profit margin: 21% (in line with FY 2021). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 8.8%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥28.50, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 117% over the past year. Reported Earnings • Oct 31
Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.17 (up from CN¥0.12 in 3Q 2021). Revenue: CN¥260.0m (up 39% from 3Q 2021). Net income: CN¥69.7m (up 38% from 3Q 2021). Profit margin: 27% (in line with 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.19 (up from CN¥0.13 in 2Q 2021). Revenue: CN¥290.1m (up 35% from 2Q 2021). Net income: CN¥75.9m (up 51% from 2Q 2021). Profit margin: 26% (up from 23% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 31%, compared to a 22% growth forecast for the Pharmaceuticals industry in China. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥218.8m (up 17% from 1Q 2021). Net income: CN¥40.9m (up 25% from 1Q 2021). Profit margin: 19% (up from 18% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 46%, compared to a 24% growth forecast for the industry in China. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥24.60, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Pharmaceuticals industry in China. Total returns to shareholders of 73% over the past year. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥25.19, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 25x in the Pharmaceuticals industry in China. Total returns to shareholders of 81% over the past year. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 22% share price decline to CN¥20.18, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 23% over the past year. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥19.99, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 8.1% over the past year. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥16.17, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total loss to shareholders of 10.0% over the past year. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.10 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥187.3m (up 16% from 3Q 2020). Net income: CN¥50.5m (up 36% from 3Q 2020). Profit margin: 27% (up from 23% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Aug 31
Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.10 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥215.4m (up 34% from 2Q 2020). Net income: CN¥50.4m (up 36% from 2Q 2020). Profit margin: 23% (in line with 2Q 2020). Reported Earnings • Apr 20
Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.52 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: CN¥721.4m (up 24% from FY 2019). Net income: CN¥157.2m (down 16% from FY 2019). Profit margin: 22% (down from 32% in FY 2019). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥17.63, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Is New 90 Day High Low • Mar 10
New 90-day low: CN¥13.10 The company is down 26% from its price of CN¥17.82 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥14.14, the stock is trading at a trailing P/E ratio of 24.3x, down from the previous P/E ratio of 28.9x. This compares to an average P/E of 30x in the Pharmaceuticals industry in China. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥15.71 The company is down 10.0% from its price of CN¥17.53 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Valuation Update With 7 Day Price Move • Jan 01
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥15.87, the stock is trading at a trailing P/E ratio of 27.3x, down from the previous P/E ratio of 32.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥15.75, the stock is trading at a trailing P/E ratio of 27.1x, down from the previous P/E ratio of 32x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Is New 90 Day High Low • Dec 29
New 90-day low: CN¥16.38 The company is down 1.0% from its price of CN¥16.52 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥206.5m, up 19% from the prior year. Total revenue was CN¥687.7m over the last 12 months, up 19% from the prior year. Valuation Update With 7 Day Price Move • Oct 19
Market bids up stock over the past week After last week's 18% share price gain to CN¥20.45, the stock is trading at a trailing P/E ratio of 39.3x, up from the previous P/E ratio of 33.4x. This compares to an average P/E of 39x in the Pharmaceuticals industry in China. 
